$2.74T
Total marketcap
$171.09B
Total volume
BTC 51.12%     ETH 15.98%
Dominance

Cancer Treatment CTHZ Stock

0.0001 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
Other OTC
Market Cap
0 USD
LOW - HIGH [24H]
0.0001 - 0.0001 USD
VOLUME [24H]
1.36K USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

Cancer Treatment Price Chart

Cancer Treatment CTHZ Financial and Trading Overview

Cancer Treatment stock price 0.0001 USD
Previous Close 0.0001 USD
Open 0.0001 USD
Bid N/A x N/A
Ask N/A x N/A
Day's Range 0.0001 - 0.0001 USD
52 Week Range 0.0001 - 0.0001 USD
Volume 2.58K USD
Avg. Volume 2.58K USD
Market Cap N/A
Beta (5Y Monthly) 1.210948
PE Ratio (TTM) N/A
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

CTHZ Valuation Measures

Enterprise Value 401.27K USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) N/A
Enterprise Value/Revenue 9.326
Enterprise Value/EBITDA -0.657

Trading Information

Cancer Treatment Stock Price History

Beta (5Y Monthly) 1.210948
52-Week Change 0%
S&P500 52-Week Change 20.43%
52 Week High 0.0001 USD
52 Week Low 0.0001 USD
50-Day Moving Average 0.0001 USD
200-Day Moving Average 0.0001 USD

CTHZ Share Statistics

Avg. Volume (3 month) 2.58K USD
Avg. Daily Volume (10-Days) 2.58K USD
Shares Outstanding N/A
Float N/A
Short Ratio N/A
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate N/A
Trailing Annual Dividend Yield N/A
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends May 31, 2002
Most Recent Quarter (mrq) February 28, 2003
Next Fiscal Year End May 31, 2003

Profitability

Profit Margin 0%
Operating Margin (ttm) -1463.25%
Gross Margin 100.00%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -28.65%
Return on Equity (ttm) -119.77%

Income Statement

Revenue (ttm) 43.03K USD
Revenue Per Share (ttm) 0.01 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 58.78K USD
EBITDA -610882 USD
Net Income Avi to Common (ttm) -1044286 USD
Diluted EPS (ttm) N/A
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 398.3K USD
Total Cash Per Share (mrq) 0.12 USD
Total Debt (mrq) 504.29K USD
Total Debt/Equity (mrq) 144.19 USD
Current Ratio (mrq) 1.052
Book Value Per Share (mrq) N/A

Cash Flow Statement

Operating Cash Flow (ttm) -828279 USD
Levered Free Cash Flow (ttm) -5329 USD

Profile of Cancer Treatment

Country United States
State NV
City Carson City
Address 202 North Curry Street
ZIP 89703
Phone 212-221-1340
Website N/A
Industry
Sector(s)
Full Time Employees N/A

Cancer Treatment Holdings, Inc., through its subsidiaries, engages in providing IT-enabled services; the exploitation of an invention related to the on-site production of chlorine gas and related compounds; and providing radiation therapy, diagnostic imaging, and other medical related services. The company, through a 50% interest in a joint venture, offers IT-enabled services, including medical transcriptions, billing and collecting, bookkeeping, and claims processing services. The company enables users to manufacture chlorine on-site and when needed through its device. It has a 51% interest in a radiation therapy center located in Logan, West Virginia. In addition, through its wholly owned subsidiary, CTI Management Corp., the company's president provides management services. The company is based in Carson City, Nevada.

Q&A For Cancer Treatment Stock

What is a current CTHZ stock price?

Cancer Treatment CTHZ stock price today per share is 0.0001 USD.

How to purchase Cancer Treatment stock?

You can buy CTHZ shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Cancer Treatment?

The stock symbol or ticker of Cancer Treatment is CTHZ.

How many shares does Cancer Treatment have in circulation?

The max supply of Cancer Treatment shares is 0.

What is Cancer Treatment Price to Earnings Ratio (PE Ratio)?

Cancer Treatment PE Ratio is now.

What was Cancer Treatment earnings per share over the trailing 12 months (TTM)?

Cancer Treatment EPS is 0 USD over the trailing 12 months.

Stocks Related By Sector

Stocks Related By Industry

Stocks Related By Marketcap